Supplementary Table 6 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Autor: Darren W-T. Lim, Luigi Manenti, Romain Séchaud, Jennifer Mataraza, Hongzi Liang, Yao Yao, Sebastian Szpakowski, Juan Gonzalez-Maffe, Steven McCune, Joël Guigay, Ammar Sukari, Alexander I. Spira, Zujun Li, Pei-Jen Lou, Victor H.F. Lee, Suebpong Tanasanvimon, Brigette B.Y. Ma, Somvilai Chakrabandhu, Po Chung Chan, Chia-Jui Yen, Li Zhang, Arunee Dechaphunkul, Roger K-C Ngan, Shau-Hsuan Li, Hung-Ming Wang, Caroline Even
Rok vydání: 2023
Popis: Supplemental Table S6. Adverse events of special interest (patients treated with spartalizumab)
Databáze: OpenAIRE